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ABSTRACT 
Andrea E. Byrnes: Quantitative Methods for Evaluating Association between Multiple 
Rare Genetic Variants and Complex Human Traits 
(Under the direction of Yun Li) 
First, we propose two methods for aggregation of rare variants in data from 
Genome-wide Association Studies (GWAS), a weighted haplotype-based approach and 
an imputation-based approach, to test for the effect of rare variants with GWAS data. 
Both methods can incorporate external sequencing data when available. Our methods 
clearly show enhanced statistical power over existing methods for a wide range of 
population-attributable risk, percentage of disease-contributing rare variants, and 
proportion of rare alleles working in different directions. We thus demonstrate that the 
evaluation of rare variants with GWAS data is possible, particularly when public 
sequencing data are incorporated. 
Second, we present a systematic evaluation of multiple weighting schemes 
through a series of simulations intended to mimic large sequencing studies of a 
quantitative trait. We evaluate existing phenotype-independent and phenotype-dependent 
methods, as well as weights estimated by penalized regression. We find that the 
difference in power between phenotype-dependent schemes is negligible when high-
quality functional annotations are available. When functional annotations are unavailable 
or incomplete, all methods lose power; however, the variable selection methods 
outperform the others at a cost of increased computational time. In the absence of highly  
 iv 
 
accurate annotation, we recommend variable selection methods (which can be viewed as 
“statistical annotation”) on top of regions implicated by a phenotype-independent 
weighting scheme. 
Finally, we propose a method to apply the Sequence Kernel Association Test 
(SKAT), a similarity-based approach for rare variant association, to data from admixed 
populations by first estimating local ancestry for each variant. In simulations, we find that 
when the true causal alleles are causal only from only one ancestral population, our 
proposed approaches show a marked improvement in power over the original SKAT 
method. In real data, our results support the previously reported European-specific 
association and illustrate the increased statistical power of the proposed methods to find 
such associations. 
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CHAPTER 1: MOTIVATION AND BIOLOGICAL JUSTIFICATION 
In this document, we will discuss statistical methods for assessing association 
between sets of rare genetic sequence variations and complex human traits. This section 
provides an overview of the biological problems we are interested in and the some of the 
statistical strategies employed in an attempt to solve them. 
To begin, DNA is a double-stranded molecule consistent of four nucleic acid 
components: Adenine (A), Cytosine (C), Guanine (G) and Thymine (T). DNA is found in 
the nucleus of the vast majority of plant and animal cells and has been compared to a 
blueprint for the organism in which it is found. Humans have 22 autosomes, in addition 
to the sex chromosomes X and Y and mitochondrial DNA, accounting for over 5 billion 
base pairs in total. We will consider primarily autosomal DNA, for which each individual 
possesses two copies, one inherited maternally and the other paternally. Over 99% of the 
DNA sequence is the same across humans (Ohno, 1972), however there are a large 
number of ways in which human DNA sequence can differ from one another in a single 
region including microsatellites, copy number variations (CNVs), insertions, deletions, 
inversions and single nucleotide polymorphisms (SNPs). Any one of these can be called a 
genetic variant, meaning that it contains a sequence of nucleic acids that is different from 
the consensus sequence or from what is most common. 
A single nucleotide polymorphism is one such genetic variant that occupies only 
one base pair. As previously stated, much of the genome is shared across humans, 
however some of these variants, SNPs included, are quite common with variant or minor 
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allele frequency (abbreviated MAF) near 0.5. Because of this, a great deal of genetic 
variation can be measured by a relatively small subset of these SNPs. In the 
1990’smicroarray technologies from companies like Affymetrix and Illumina began to 
capitalize on these common SNPs in the form of genome-wide SNP platforms. Today 
these technologies can accurately assess up as many as 1 million pre-selected SNPs [e.g. 
the Affy Axiom or Illumina 1M], however these technologies are limited in that they 
cannot discover new variants. Though rare variants outnumber common ones (1000 
Genomes Consortium et al., 2010; Mathieson & McVean, 2012), rare variants are seldom 
included in GWAS panels since they contain little information in relatively small sample 
sizes. This stands to reason since a marker that is not polymorphic or barely polymorphic 
in a sample provides little or no statistical power to detect association between the single 
SNP and the outcome of interest.  
GWAS studies yielded promising genetic loci in association with many complex 
human traits such as coronary artery disease, diabetes, bipolar disorder, rheumatoid 
arthritis, obesity and height (Frayling et al., 2007; Weedon et al., 2008; WTCCC, 2007), 
but ultimately could not explain the extent to which these traits appear to be inherited. 
This phenomenon came to be known as “missing heritability” (Maher, 2008; Manolio et 
al., 2009). Some investigators proposed that the apparent missing heritability was due to 
rare or even private mutations and that association testing for these types of variants was 
not possible without whole sequence data on thousands of individuals, if at all. These 
authors advocated abandoning large scale GWAS for complex traits (Goldstein, 2011). 
Others argued that the missing heritability could also be due to several relatively common 
variants of modest effect size and that current GWAS sample sizes were not large enough 
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to elucidate these associations. (Sullivan, 2012) The GWAS study design remains 
popular, partially due to the emergence of genome imputation for variants not typed. 
Though rare variants are not typed by the GWAS chips themselves, imputation methods 
use information from an outside panel such as HapMap or 1000 Genomes to predict the 
genotypes of markers not in the GWAS panel, including some rare variants, via Markov 
Chain Monte Carlo (Y. Li, Willer, Ding, Scheet, & Abecasis, 2010; Y. Li, Willer, Sanna, 
& Abecasis, 2009; Marchini & Howie, 2010). 
From 2009 to the present, “next generation” sequencing technologies have 
brought the cost of whole exome and whole genome sequencing down to hundreds of 
dollars per sample. These rapid advances in technology allowed investigators to collect 
larger samples (hundreds or thousands of individuals) that evaluate every base of the 
genome (or exome), which was previously unimaginable due to cost. Investigators can 
now evaluate thousands of known rare variants and discover previously unknown 
variants with these technologies. However, for rare variants, evaluating each variant 
independently as in GWAS analysis requires a sample size far greater than even these 
studies can provide. Further if, a variant is unique to one individual, or “private,” no 
study design will discover this causal relationship if each variant is evaluated one at a 
time. Because of this, the idea of combining information from multiple variants across a 
genomic region, gene or pathway became increasingly popular. 
Previously, we have discussed the MAF as a fixed quantity; however, data from 
Hapmap (International Hapmap Consortium, 2005) and 1000 Genomes (1000 Genomes 
Consortium et al., 2010) demonstrate that MAF can vary greatly across populations. In 
fact, the existence of a particular variant can be population-specific. When dealing with 
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data from a single ancestral population, this does not change the conclusions greatly; 
however, when two or more populations are present in the study sample these differences 
can quickly lead to incorrect results. In particular, populations in which more than one 
ancestral population’s genetic contribution is present in most or all of the individuals, e.g. 
African American or Hispanic populations, can be especially complicated. Such 
populations are known as admixed populations and many methods have emerged to 
adjust for the complexity they bring to genetic studies. 
This compilation of projects attempts to survey and compare the methodology of 
several existing methods for the aggregation of rare variants across a genomic region 
(e.g. gene, exon, pathway). We also aim to improve upon some of these methods and 
adapt them for use in admixed populations. The next section deals with the history rare-
variant collapsing methods and their evolution from simple counting methods, to more 
complex systems of weighting that utilize phenotype information, and finally, to 
similarity-based methods which use more complex statistical techniques to assess 
genomic similarity between individuals and their trait of interest. 
The third chapter proposes two methods, a weighted haplotype-based approach 
and an imputation-based approach, to test for the effect of rare variants with GWAS data. 
Both methods can incorporate external sequencing data when available. We evaluated our 
methods and compared them with methods proposed in the sequencing setting through 
extensive simulations. Our methods clearly show enhanced statistical power over existing 
methods for a wide range of population-attributable risk, percentage of disease-
contributing rare variants, and proportion of rare alleles working in different directions. 
We also applied our methods to the IFIH1 region for the type 1 diabetes GWAS data 
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collected by the Wellcome Trust Case-Control Consortium. Our methods yield p-values 
on the order of 10-3, whereas the most significant p-value from the existing methods is 
greater than 0.17. Therefore, we demonstrate that the evaluation of rare variants with 
GWAS data is possible, particularly when public sequencing data are incorporated. This 
work was published in the American Journal of Human Genetics in 2010 (Y. Li, Byrnes, 
& Li, 2010). 
The forth chapter presents a systematic evaluation of multiple weighting schemes 
through a series of simulations intended to mimic large sequencing studies of a 
quantitative trait. We evaluate existing phenotype- independent and phenotype-dependent 
methods, as well as weights estimated by penalized regression approaches including 
Lasso (Tibshirani, 1996), Elastic Net (Zou & Hastie, 2005), and SCAD(Xie & Huang, 
2009). We find that the difference in power between phenotype-dependent schemes is 
negligible when high-quality functional annotations are available. When functional 
annotations are unavailable or incomplete, all methods suffer from power loss; however, 
the variable selection methods outperform the others at the cost of increased 
computational time. Therefore, in the absence of good annotation, we recommend 
variable selection methods (which can be viewed as “statistical annotation”) on top of 
regions implicated by a phenotype-independent weighting scheme. Further, once a region 
is implicated, variable selection can help to identify potential causal single nucleotide 
polymorphisms for biological validation. These findings are supported by an analysis of a 
high coverage targeted sequencing study of 1,898 individuals. 
The final section proposes a combination method to apply the SKAT similarity-
based approach (Wu et al., 2011) to data from admixed populations by first estimating 
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local ancestry for each variant using Hapmix (Price et al., 2009) and MaCH-Admix (Liu, 
Li, Wang, & Li, 2013). We find that when the true causal alleles come only from the less 
common ancestral population, this approach shows a marked improvement in power over 
the original SKAT method alone. When the true causal alleles come only from the more 
prevalent ancestral population, however, the SKAT approach alone seems adequate to 
capture the association signal. This work is not yet complete, but we outline the proposed 
next steps in the final part of this section, which include more simulation replicates and 
the application to a real data set. 
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CHAPTER 2: LITERATURE REVIEW 
 This section presents a partial review of many of the papers previously published 
on the topic of collapsing information across rare variants. It is by no means complete 
since the number of these papers is quite large; however, it is an attempt to show the 
development of several methods used to attack this problem. Mathematical notation 
between the works discussed here is also quite diverse, so n the description of many of 
these works, some of the mathematical notations (variable names, etc.) has been altered 
slightly to keep the notation as consistent as possible throughout this document. 
2.1 Early Methods 
Before the advent of high-throughput genomic sequencing, it had been 
hypothesized that collections or combinations of rare variants could be responsible for 
some of the heritability in human complex traits. When GWAS and other studies turned 
up promising candidate genes, many researchers invested in re-sequencing and other 
molecular experiments in order to learn more about these candidates. The first methods 
for association of rare genomic variants arose from the need to analyze these data. 
Well before the rise of “next generation” genome sequencing technologies, 
(Cohen et al., 2004) demonstrated that rare alleles could indeed have a measureable effect 
on human traits. Cohen et. al. sampled 128 individuals from the top and bottom five 
percent of the HDL cholesterol distribution in the Dallas Heart Study. All subjects were 
sequenced for three candidate genes, ABCA1, APOA1 and LCAT. Non-synonymous 
mutations (that is, variation that effects the resulting protein) were considerably more 
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common in the low HDL group as compared to the high HDL group, most notably in 
ABCA1, (p<0.0001). The investigators reported that one in six individuals with low HDL 
had a rare mutation in ABCA1 or APOA1 and went on to replicate these findings in a 
Canadian sample, thus making a strong case for the involvement of rare sequence 
variants in complex disease. These investigators did not develop a novel statistical 
method for assessing the combined effects of rare variants on the genome-wide scale, but 
they did demonstrate the potential impact of considering associations with combinations 
of rare variants. Note also that the rare variants were found primarily in the low HDL 
group, suggesting that these variants exhibit a protective effect. It had been previously 
suggested that genetic variants can, in most cases, be assumed to have null or deleterious 
effect. Variants of protective effect were (and are still) considered the exception, rather 
than the rule. However, the results of this study show the importance of detecting 
association between genetic variants and human phenotypes in either direction. 
As the interest in rare variation grew, so too did the interest in capturing their 
associations statistically. An approach similar to that described above was formalized by 
(Morgenthaler & Thilly, 2007). In their manuscript, the authors emphasized the 
importance of limiting these tests to promising genes and adjusting for many important 
biological variables such as the number of genes and variants expected to be truly 
involved in the etiology of the trait. In this work, Morgenthaller and Thilly focused 
primarily on case-control studies and they suggested using the rare variant count among 
cases compared that of controls to conduct a T-test for association between the rare 
variant “burden” and the disease of interest. They named this method cohort allelic sum 
 9 
 
test (CAST). Note that this test only compares counts of rare alleles, and so information 
must be pooled across individuals and across markers. 
In 2008, Li and Leal proposed the Combined Multivariate and Collapsing (CMC) 
method to collapse across variants across genomic regions, functional groups, MAF 
categories or other groupings (B. Li & Leal, 2008).  These authors advocated first 
splitting the M markers into k groups (for example, by MAF bin) and then using a 
collapsing method in which, for each individual i, in the set of variants under study, Li 
and Leal suggested computing Xi as follows, 
Xi =
1,
0,
rare variants present
rare variants absent
⎧
⎨
⎪
⎩⎪
 
so that any individual with rare variants present was given weight 1 and all others have 
weight 0. This reduced the dimension of the multivariate test from M to k, making a 
multivariate test feasible where it may not otherwise be. Unlike the approach of 
(Morgenthaler & Thilly, 2007), Li and Leal collapsed information across markers, within 
individual, for each group k. The authors reported good results for situations in which one 
or more rare variants in the same group were truly deleterious. 
 In the same year, (M. Li, Wang, Grant, Hakonarson, & Li, 2009) proposed a 
method to use the information contained in outside data sets (e.g. HapMap) to better 
assess association between traits and genotypes called ATOM. Genotype imputation had 
also been helpful in gaining information about un-typed markers in GWAS studies (Y. 
Li, Willer, et al., 2010; Y. Li et al., 2009); however, unlike the imputation study design, 
ATOM did not require that each un-typed variant be explicitly imputed. ATOM aimed to 
assign weights in markers based on the amount of association they have with the trait 
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locus, which was assumed to be un-typed. It did so by capitalizing on the correlation or 
linkage disequilibrium (LD) structure of the region. Suppose that the external data set has 
Me markers and Me > M. For each pairwise combination of variants in the original data 
set, j ∈{1,2,...,M} , and each marker in the external data set l ∈{1,2,...,Me} , the weight 
wjl  is computed, 
wjl =
Δ j
l
q j (1− qj )
, 
where qj is the minor allele frequency at variant j from the reference data and Δ j
l  is the 
linkage disequilibrium (LD) coefficient for markers l and j. Then, for each of the markers 
in the external data set, l ∈{1,2,...,Me}  the authors computed the score, 
Sil =
1
m wj
l xij
j=1
M
∑  
so each individual had Me scores. Then the authors performed principal component 
analysis (PCA) on these scores, thus reducing the dimension of the problem significantly. 
The principal components were then tested for association with the trait by conventional 
regression methods without permutation. ATOM performed well compared to other 
previous methods in terms of power and also performed well when compared to simple 
haplotype approaches not discussed here. 
In 2009, Madsen and Browning similarly hypothesized that rarer variants were 
more likely to have deleterious effects and that a higher burden of rare variants should 
likewise be more harmful than one lone rare variant. With this motivation, they proposed 
a simpler method that does not rely on an external dataset called the Weighted Sum (WS) 
method for case-control data. (Madsen & Browning, 2009) These investigators used the 
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estimated minor allele frequency (MAF) of marker j among controls, denoted qj, where, 
qj =
xij
i=1
Ncontrol
∑ +1
Ncontrol + 2
 to construct weights, wˆ j = Ntotalqj (1− qj )  so that, the rarer the allele, the 
smaller the quantity wˆ j . Madsen and Browning then computed the genetic scores for 
each individual, denoted Si =
xij
wˆ jj=1
M
∑ . Thus, the largest components of this weighted sum 
came from the variants rarest among controls. This stands to reason since deleterious 
alleles may confer a selective disadvantage and therefore be less common in the 
population than neutral or beneficial ones. Madsen and Browning performed a Wilcoxon 
Rank Sum test on the collection of Si’s to assess significance. The many simulations 
presented in the Madsen and Browning manuscript show the Weighted Sum (WS) 
method distantly outperforming CAST, CMC and single variant tests in terms of power to 
detect rare variant association in a number of situations. They also demonstrated their 
methods’ improved power by applying it to the ENCODE data. 
In the following year, Price et. al. proposed a similar method to allow for an 
unknown threshold on MAF, denoted T, below which variants may be substantially more 
indicative of a functional variant (Price et al., 2010). As motivation for the idea, Price, et. 
al. first constructed a weighted sum with a fixed threshold, T, and constructed genetic 
scores, Si = ξ j (2− xij )yi
j=1
M
∑  where ξ j = I(qj < T )  and yi is the outcome of interest. The 
authors evaluated both T=0.01 and 0.05. Price et. al. then generalized this approach to 
their Variable Threshold (VT) method by constructing a Z-scores, Z(T), for a range or T 
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values. The Z-score Z(t) is constructed,Z(t) = ξ jT (2− xij )(yi − y )
i=1
N
∑
j=1
M
∑ , where y =
1
N yii=1
N
∑  
is the mean of the outcomes yi. The value of T that maximizes Z(t) in each case was then 
chosen as the threshold. Because of this step, the Wilcoxon Rank Sum test was no longer 
valid and statistical significance needed to be assessed by permutation. The authors found 
their VT approach had greater power than WS and fixed-threshold methods in 
simulations for both dichotomous and continuous outcomes. (Price et al., 2010) also 
applied their VT method to Polyphen-filtered data (Ramensky, Bork, & Sunyaev, 2002) 
and found a greater improvement in power with the addition of good bioinformatics data. 
Also in 2010, a manuscript in Genetic Epidemiology (Morris & Zeggini, 2010) 
presented a simple experiment demonstrating the importance of the choice of weighting 
scheme for these types of approaches and the potential for falsely significant results due 
to non-causal rare variants. The authors tested two scoring methods, which they call 
RVT1 and RVT2. RVT1 constructed weights for predefined genomic regions according 
to the proportion of rare variant sites at which an individual i had 1 or 2 copies of the 
minor allele, thus fitting the following model. 
yi =α +λ
I(xij > 0)I(qj < T )
j=1
M
∑
I(0 < qj < T )
j=1
M
∑
+γZi +εi , where εi ~ N(0,σ 2 ) , Zi is a vector of covariates 
and T is the threshold for determining the definition of “rare” in this case. Morris and 
Zeggini’s other model, named RTV2, assigned weights out of an indicator function, 
which took value 1 when any rare variant sites contained one or more copies of the minor 
allele in individual i and 0 otherwise. 
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yi =α +λI I(qj < T )xij
j=1
M
∑ > 0
"
#
$$
%
&
''+γZi +εi , where εi ~ N(0,σ
2 )  and Zi and T are as before. 
The authors found that the weighting scheme based on the proportion of rare variant sites 
(RVT1) with one or more minor alleles had equal or greater power to the method that 
only considers whether rare variants are present or not. Morris and Zeggini demonstrated 
that this power difference was most pronounced when the number of non-causal rare 
mutations increases. Since RVT1 gave larger weight to individuals with a larger burden 
of rare variants, these same individuals were more likely to carry one or more rare 
deleterious variants. 
2.2 Using the outcome to inform choice of weights 
Though diverse, the early methods for rare variant association demonstrated the 
importance of combining the data in an intelligent way, rather than simply searching for 
the presence or count of rare variants. Many of these methods were devised for 
application to GWAS data and GWAS data after imputation using an outside reference 
panel, as described in the previous section. The advent and refinement of “Next 
Generation” sequencing technology only made such methods more appealing and, in a 
relatively short period of time, a plethora of new methods arose, many of them attempted 
to directly estimate a weight for each marker by explicitly using the outcome 
measurements. In this section, we will outline several such previously proposed methods 
for binary and continuous outcomes. 
 To start, (Han & Pan, 2010) described a method to use the information from 
individual markers via marginal logistic regression coefficient estimates for case-control 
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data. Han and Pan suggested first fitting a series of univariate regression models of the 
form, 
logit Pr(Yi =1) = β0 + xijβ j  
where Yi is the case or control status of individual i, and xij is the genotype for individual i 
at locus j as before. From each such model, the estimated coefficient, β j , and a p-value, 
pj, were used to estimate the weight for each marker. First, the genotype data was recoded 
such that, 
xij* =
xij,
2 − xij,
if β j ≥ 0 and pj <α0
if β j < 0 and pj <α0
⎧
⎨
⎪
⎩⎪
, 
where α0  is a predetermined p-value threshold, so that the coefficient, 
βˆc =
xij*2 β j
j=1
M
∑
i=1
N
∑
xij*
j=1
k
∑
⎛
⎝⎜
⎞
⎠⎟
2
i=1
N
∑
 
from the model, logit Pr(Yi =1) = β0 + xijβc
j=1
M
∑ , which assumes (probably incorrectly) that 
all variants with causal effect had the same odds ratio. The authors tested the hypothesis 
H0 : βc = 0  with the usual score test. Despite the questionable assumption of a constant 
odds ratio for all causal variants, this method performed well in comparison to previous 
methods in terms of power and type I error. Also note that, because the data were used to 
estimate the weight each variant received in the analysis, analytical p-values could not be 
evaluated here. Instead, the authors advocated a permutation approach in which the Yi are 
shuffled randomly to attain a correct p-value. 
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In 2011, Zhang et. al proposed a similar method that also used the results of single 
marker tests in to inform the choice of weights for each marker (Zhang, Irvin, Arnett, 
Province, & Borecki, 2011). Assume single marker tests via linear (for continuous 
outcomes) or logistic (for binary outcomes) have already been conducted and for each 
marker, we have an estimate of the coefficient for marker j, bj and the standard error of 
that estimate, sbj. The investigators proposed fitting the model, 
Yi =α + β wjxij
j=1
M
∑ + ε i  
where xij in the number of minor alleles at locus j for individual i and wj is the weight 
assigned to marker j determined by, 
wj = 2{p(t ≤ t j )− 0.5},  with t j =
bj
sbj
. 
where the distribution of t is determined empirically from all of the single marker tests 
conducted. The probability p(t ≤ t j )  is a left tail p-value, and so the test was named the p-
value weighted sum test (PWST). In order to assess significance, the authors simply 
tested the hypothesis, H0 : β = 0 . PWST was also shown to perform well compared to 
phenotype-independent approaches. 
In 2011, Lin and Tang rigorously showed that the optimal unbiased weight for 
each variant was proportional to the true coefficient β j  in the limit. (Lin & Tang, 2011) 
Since the coefficient could be estimated from the data, it seemed sensible to set , 
where βˆ j  is the appropriate estimate of the coefficient β j . However, the authors pointed 
out two problems with this approach. First, using these weights, their test statistic T 
would not be asymptotically normal and, second, the values of βˆ j  were relatively 
ξ j = βˆ j
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unstable considering that the variants in question are rare and the sample size was finite. 
The authors instead proposed a compromise in which they fit the model, 
Yi =αi0 +αi + β j xij +εi
j=1
M
∑ , where εi ~
iid
N(0,σ 2 )  is assumed and construct weights
, where delta is a known constant. Then the genetic score was constructed, as 
in previous methods, Si = ξ j xij
j=1
M
∑ , and evaluated with a score statistic. The authors 
named this method EREC (Estimated Regression Coefficients) and found it performed 
well is simulations and on real data, though some of the similarity approaches (discussed 
in the next sub-section) produced smaller p-values when applied to real data. The EREC 
method cannot be applied in cases where M>N and is not intended to account for variant 
effects in different directions. 
In the same year, a Bayesian method that used the data to directly estimate the 
weights of the individual markers, in addition to assessing to significance of the 
association between genotypes and trait (as in EREC), was proposed by (Yi & Zhi, 
2011). Since this method was intended for use on case-control data, the investigators 
ultimately aim to fit the logistic model, logit Pr(Yi =1) = β0 + xijβ j
j=1
M
∑ , which they 
rewrote as logit Pr(Yi =1) = β0 + β xijα j
j=1
M
∑ . They then rephrased the problem, first 
estimating the α j, j ∈{1,2,...,M} , and then testing, H0 : β = 0 . Yi and Zhi offer a 
different solution to the problem of instability for the estimates of the individual weights 
ξ j = βˆ j +δ
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from (Lin & Tang, 2011) by putting priors on the parameters α j  and β . The authors 
proposed an informative prior on the α j ,  
α j ~ N(µ j,τ j2 ),  τ j2 ~ Inv − χ 2 (1, sα2 )  
where sα2  was chosen to be a small value such as 0.5. Yi and Zhi point outed that the 
choice of the Student-t priors on α j  are designed to better deal with disparate effects. 
The prior parameter µ j  could be manipulated according to the prior knowledge about the 
variant j, and though the authors did not do this, they suggested using frequency 
distribution or functional credibility to determine the value of µ j . Because of the rarity 
of the alleles in question, the variance of xijα j
j=1
M
∑  could be quite low and so, the estimate 
of β  could also become unstable, the authors suggested a weakly informative prior on β  
β ~ N(0,τ β2 ),  τ β2 ~ Inv − χ 2 (1, 2.52 )  
which was meant to keep the β  parameter in a reasonable range. This Bayesian linear 
model was fitted using Markov Chain Monte Carlo and showed good results for type I 
error and power far surpassing any of the phenotype-independent methods discussed in 
the previous sub-section. This gain in power was particularly noticeable when the effects 
of the causal variants acted in opposite directions. This method was not, however, 
compared to any other phenotype-dependent methods previously discussed. 
2.3 Similarity-based approaches: why weight?  
Simultaneously with many of the methods discussed above, many statistical 
geneticists and biostatisticians began to question if weighting each individual marker was 
necessary at all. While having weights for individual markers may be helpful in 
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determining the disease etiology in some cases, simply implicating a gene or molecular 
target can also be helpful to biological and pharmaceutical researchers. The above 
methods directly estimate a weight for each marker, but the following methods are aimed 
at implicating a genomic region by collapsing sets of markers that tend to be shared 
across two individuals when the outcomes are also similar. 
One of the first of such methods was proposed well before the popularization of 
“next generation” sequencing techniques by (Schaid, McDonnell, Hebbring, 
Cunningham, & Thibodeau, 2005). Schaid and colleagues suggested using a U-statistic of 
the form, 
Uglobal =
K(xi, xi ' )
i<i '
∑
N
2
⎛
⎝⎜
⎞
⎠⎟
= wj
K(xij, xi ' j )
i<i '
∑
N
2
⎛
⎝⎜
⎞
⎠⎟
j=1
M
∑ = wjU j
j=1
M
∑  
where K(xi, xi ' )  is a symmetric kernel function that compares the genotype of individual i 
to that of individual i’. Specifically, it is the weighted sum of the variant- 
specific kernels, 
Uj =
K(xij, xi ' j )
i<i '
∑
N
2
⎛
⎝⎜
⎞
⎠⎟
. 
The authors suggested two kernels with which to quantify the similarity of individual i 
and i’ at locus j: first the “allele-match” kernel, which was a simple count of the number 
of alleles at locus j that match between individuals i and i’. Second, the “linear dosage” 
kernel added the number of the minor alleles at locus j together for individuals i and i’. A 
normalized version of these U-statistics were compared to several simpler methods, such 
as simply taking the maximum signal from the region and the conventional multivariate 
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T-test with good results for power and type I error under most conditions, particularly 
when the number of risk loci rose above 5. 
(Neale et al., 2011) also suggest a method to test for any association between a set 
of genotypes and phenotype rather than individually estimating weights for each marker. 
For motivation, the authors used the example of set of M coins that could be either fair or 
biased. Each coin could land as either a case or a control and, if the coin was fair, it 
would land case and control with equal probability. If the coin was biased (i.e. if the 
marker is associated with the trait in either direction), they expected the coin to land 
preferentially as a case or as a control. Thus, the Cα tests for the presence of biased coins 
over the M markers, rather than a test for single biased coin. The Cα  test statistic 
compares the variance of each observed count with the expected variance and then sums 
over all variants. 
T = [(xcase, j − xtotal, j p0 )2 − xtotal, j p0 (1− p0 )]
j=1
M
∑  
where p0 is the expected number of times the minor allele is expected to turn up in the 
cases, given the number of total copies of the minor allele in the sample and assuming 
that the jth marker is like a fair coin, that is p0 =
xtotal, j
2  for xtotal, j ≥ 2 . The obvious 
problem with this setup was singleton counts, since they contain no variance information. 
The authors suggested binning all of the singleton counts into one category and 
proceeding as if they were all from one marker. The quantity T was then normalized and 
compared to a one-tailed normal distribution. The Cα  test performed well in terms of 
power when compared to simple burden tests like that of (B. Li & Leal, 2008; Madsen & 
Browning, 2009), however the asymptotic properties of the proposed statistic had heavier 
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tails that expected, particularly when the sample size is small. Further, this test assumed 
independence between all variants and for all these reasons, the authors suggested using 
permutations to assess significance particularly in the presence of LD or when sample 
size is small. 
Later in 2011, Wu and Lee et. al. suggested a more general test with an arbitrary 
weight matrix also using kernel methodology to compare the genomes of all N samples 
called SKAT (Wu et al., 2011). As with many of the methods considered above, SKAT 
aimed to fit a model of the form, Yi = µ + βX  that may or may not also have covariates 
included in the µ  component. They proposed a statistic Q of the form,  
Q = (Y − µˆ)'K(Y − µˆ) ,  where K = XWX '  
in which X is the N ×M  matrix of minor allele counts, as before and W is a matrix of 
weights that can be specified by the users. Wu, Lee and colleagues explored several 
kernels to incorporate information from various data types to provide a more powerful 
test. The matrix K was constructed to measure the pairwise genotypic similarity between 
every two individuals in the sample. The matrix W quantifies the degree of importance 
each variant. In the absence of a user derived weight matrix, the SKAT authors 
recommend using a matrix K such that K(xi, xi ' ) = wjxij xi ' j
j=1
M
∑  when no interactions 
between variants are present (linear kernel) and K(xi, xi ' ) = 1+ wjxij xi ' j
j=1
M
∑
⎛
⎝⎜
⎞
⎠⎟
2
 for when 
there are interactions between variants (quadratic kernel). They suggested choosing the 
weights according to wj = Beta(qj,1, 25)  where qj is the MAF of variant j, as before. The 
SKAT authors saw power that was much improved compared to the burden tests and 
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advocate this method over the Cα  test because it can easily account for covariates and 
interactions between variants. 
Interestingly, the SKAT authors noticed a drop in power when the true situation 
(unknown in the case of a real study) was similar to that in which the Madsen & 
Browning method (Madsen & Browning, 2009) is ideal. That is, situations where the trait 
was influenced, not by a particular subset of rare genetic variants, but by the number of 
deleterious, rare “hits” observed in the region. In 2011, Lee and colleagues proposed 
SKAT-O to optimize the test, even if this was the case (Lee et al., 2012).  SKAT-O 
performed both the SKAT test and the burden test and produces a weighted sum of the 
two. In situations where the SKAT statistic would be most powerful, SKAT-O lost very 
little power in comparison to SKAT; however, SKAT-O demonstrated a marked 
improvement over the original SKAT approach when the true association was a series of 
very low frequency hits. 
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CHAPTER 3: WHAIT 
3.1 Introduction 
In this chapter, we propose two methods to search for the aggregated effect of rare 
variants with GWAS data. Our approaches do not rely on the availability of external 
sequencing data, but they can incorporate such information when available. Moreover, 
our methods make no assumption on the direction of association of rare alleles with 
disease risk. We applied our methods, along with existing methods proposed in the 
sequencing context, to simulated data sets. Our methods demonstrated better performance 
across a wide range of scenarios with an average power improvement of 8.6% (31.6%) in 
the absence (presence) of external sequencing data. We also applied our methods to the 
Wellcome Trust Case-Control Consortium (WTCCC) type 1 diabetes (T1D) GWAS data 
set in the IFIH1 gene region, where both common and multiple rare variants have been 
found to influence the risk of T1D (Barrett et al., 2009; Nejentsev, Walker, Riches, 
Egholm, & Todd, 2009; Smyth et al., 2006). 
3.2 Methods 
3.2.1 Weighted haplotype score test 
Our first test is a weighted haplotype test. Assume a sample of N diploid 
individuals is collected, among which Ncs are affected cases and Nct are unaffected 
controls. Let m denote the number of genotyped markers in a region of interest. Further 
denote haplotypes of the N individuals by H = (H1, H2, ..., Hi, ..., HN)t, where  
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Hi = {Hi,1, Hi,2} are the two haplotypes carried by the ith individual, consisting of the m 
markers in the region. For each individual i, we define a weighted haplotype score  
as follows: 
WHSi = WHij
j=1
2
∑ , 
in which the sum is taken over the two haplotypes of individual i. Wh stands for the 
weight of haplotype h and is defined as 
Wh = I(h∈C) ⋅(−1)I (h∈P) ⋅Sh , 
in which C is the set of disease-contributing haplotypes including both risk and protective 
haplotypes, P is the set of disease-protective haplotypes (note that P is a subset of C), and 
Sh is a score assigned to haplotype h. Following the weighting scheme proposed by 
Madsen and Browning (Madsen & Browning, 2009) for SNPs, we define Sh as 
Sh = Nct ⋅ fct,h ⋅(1− fct,h ) , 
in which fct,h denotes the adjusted frequency of haplotype h among controls and is defined 
as  
fct,h =
Cct,h +1
2(Nct +1)
, 
in which Cct,h is the number of haplotype h among controls. The rationale of using such a 
score is that a rare variant (most likely untyped in GWAS) is more likely to be tagged by 
a rare haplotype than by a common haplotype, and thus rare haplotypes should receive 
more weight in the analysis. To define the sets of the disease-contributing and disease-
protective haplotypes, we first split the data into a testing set and a training set and then 
compared the haplotype frequencies between cases and controls in the training set 
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according to the formula below: 
h∈C
h∈P
if
if
fcs,htr − fct,htr > µ
fct,htr (1− fct,htr )
2Ncttr
,
fcs,htr − fct,htr < −µ
fcttr (1− fcttr )
2Ncttr
,
⎧
⎨
⎪
⎪⎪
⎩
⎪
⎪
⎪
   (Equation 1) 
with tr standing for “training set.” Here, µ  is a constant that is determined by a pre-
specified type I error rate. For example, µ = 1.28 (1.64) corresponds to a type I error of 
0.2 (0.1). Following (Zhu, Feng, Li, Lu, & Elston, 2010) we set µ = 1.28 and randomly 
selected 30% of the samples for training in the analysis. 
We note that by explicitly modeling the two sets of haplotypes as described 
above, we do not need to make assumptions about the direction of association between 
rare alleles and disease risk. Weighted haplotype scores are calculated in the testing set 
after identifying the two sets of haplotypes with the training set. To assess whether the 
rare variants are significantly associated with the disease, we can perform a standard 
Wilcoxon (Wilcoxon, 1945) test on the weighted haplotype scores and assess the 
significance of the test by permutations. For each permuted data set, the training set and 
the testing set will be obtained in a similar fashion as the original data set. Because 
typical GWAS data consist of genotypes rather than haplotypes, we need to infer 
haplotypes from unphased genotypes. This step can be done via standard phasing 
methods, including PHASE, fastPHASE, MaCH, and Beagle (Browning, 2006; Y. Li et 
al., 2009; Scheet & Stephens, 2006; Stephens & Scheet, 2005). We used MaCH, which 
allows the incorporation of external genotyping, haplotyping, or sequencing data. Our 
weighted haplotype approach can be applied to haplotypes consisting of GWAS markers 
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alone or to haplotypes including additional markers via incorporation of external 
reference data. 
3.2.2 Weighted dosage score test 
 Our second test is a weighted imputation dosage test. Following the notations 
defined above, we assume that there are a total of M markers genotyped or sequenced 
after the incorporation of one or more external data sets, e.g. the International HapMap 
Project (Frazer et al., 2007; International Hapmap Consortium, 2005) or the 1000 
Genomes Project (Kaiser, 2008). We have previously described a hidden Markov model-
based method that imputes untyped markers in study samples by exploiting external data 
as reference, which was implemented in software MaCH and has become standard in 
GWAS analysis (de Bakker et al., 2008).  Let D = (D1, D2, ..., Di, ..., DN)t denote the 
dosage matrices across M markers for the N study subjects, in which Di = (Di,1, Di,2, ..., 
Di,j, ..., Di,M) denotes the dosages of the ith individual. Here Dij is the dosage for the ith 
individual at marker j, which is defined as the expected number of the rare allele at 
marker j. Now we define the weighted dosage score for each individual i as 
WDSi = I( j ∈MC ) ⋅(−1)I ( j∈MP ) ⋅Di, j
j=1
M
∑ , 
in which the summation is taken over all M markers with genotype dosage scores. Here 
MC is the set of markers with the rare allele that contributes to disease risk, and MP is the 
set of markers with the rare allele that decreases disease risk. We define these two sets by 
examining frequency difference between cases and controls, similar to Equation 1, for the 
weighted haplotype test. After obtaining the scores, the standard Wilcoxon test is applied 
to test for association with the disease, and its significance is assessed via permutation. 
We compared our proposed methods with the following three methods proposed in the 
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sequencing context. (1) Weighted SNP Test (denoted by WS) (Madsen & Browning, 
2009) is a weighted- sum method in which rare alleles are aggregated and weighted 
according to a function of minor allele frequency among controls. Despite the fact that 
the method was proposed as a test for ‘‘rare mutations,’’ it indeed sums over all markers 
by giving smaller weight to alleles with higher frequency. Although an omnibus regional-
based test that evaluates both common and rare variants is some- times desired, here we 
are interested in a regional-based test for rare variants only, assuming that common 
variants have been thoroughly evaluated by large-scale GWAS. Because of this, we 
compared our methods with both the originally proposed test (denoted by WSall) and a 
modified version of it (denoted by WSrare), in which only markers with minor allele 
frequency (MAF) < 5% are included. (2) (Zhu et al., 2010) proposed a haplotype 
grouping method (denoted by HG) that counts the number of rare risky haplotypes for 
each individual and uses a Fisher’s exact test for testing. (3) We also applied the rare 
variant collapsing method (denoted by RVC) proposed by (B. Li & Leal, 2008) which 
groups each individual into one of two groups: carrying any rare allele or not. Together 
with case-control status, a 2× 2 table is generated, and a standard test for contingency 
table (e.g., chi-square test for independence) is applied. Table 3.1 lists the above-
described tests and their abbreviations. 
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Table 3.1. Abbreviation and description of tests applied 
Test Abbreviation Description 
WDS Weighed dosage test on genotyped plus imputed SNPs with 
external sequencing data 
WHS Weighted haplotype test on genotyped plus imputed SNPs with 
external sequencing data 
WHG Weighted haplotype test on genotyped SNPs only 
HG Haplotype grouping test orioised by Zhu et. al. 
WSall Original weighted SNP test aggregating evidence over all 
(regardless of MAF) SNPs proposed by Madsen and Browning 
WSrare Modified weighted SNP test aggregating evidence over rare 
(MAF<5%) SNPs only 
RVC Rare variant collapsing method proposed by Li and Leal 
 
3.2.3 Simulation Setup 
We simulated 10,000 chromosomes for a series of 100 1 Mb regions with a 
coalescent model that mimics linkage disequilibrium (LD) in real data, accounts for 
variations in local recombination rates, and models population history, consistent with the 
HapMap CEU (CEPH people from Utah, USA) samples (Schaffner, Foo, & Gabriel, 
2005). We then took a random subset of 1000 simulated chromosomes (i.e., 500 
individuals) to serve as the external reference, mimicking the targeting sample size for 
the 1000 Genomes Project. To generate a set of GWAS markers in each region, we first 
randomly picked 120 chromosomes, mimicking Phase II HapMap CEU data. We then 
ascertained and thinned polymorphic sites to match marker density and allele frequency 
spectrum of their real-data counterparts. Based on LD measures calculated with the 120 
chromosomes, we selected a set of 100 SNPs for each region that included 90 tagSNPs 
tagging the largest number of SNPs and 10 additional SNPs picked at random among the 
remaining SNPs. The final set of retained SNPs (GWAS markers in the region) captured 
~78% of the common variants (MAF > 5%) at a conventional r2 cutoff of 0.8, similar to 
the real-data performance of the Illumina HumanHap300 BeadChip SNP genotyping 
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platform. 
Within each simulated 1Mbregion, we picked an ~50 kb region as the causal 
region in which we assume only rare variants (variants with population MAF between 
0.1% and 5%) contribute to the disease risk. We randomly selected d% of the rare 
variants in the causal region to be causal, i.e., to influence disease risk. Among these rare 
variants, we further assume that r% of them increase disease risk, whereas the remaining 
(100 – r)% decrease disease risk. To ensure that each variant only has a small 
contribution to the overall disease risk, we followed a model similar to that proposed by 
(Madsen & Browning, 2009). Specifically, the contribution of each causal variant j to the 
overall genotype relative risk (GRR) is defined as: 
GRRj =
PAR
(1− PAR) ⋅MAFj
+1⎛
⎝⎜
⎞
⎠⎟
(−1)I (ξ j=1)
, 
in which PAR is the population attributable risk and ξ j =1  indicates that the rare allele of 
marker j decreases disease risk. Following (Madsen & Browning, 2009), we used the 
same marginal PAR for each causal variant, which intrinsically assumes that alleles with 
lower frequency have higher GRR than alleles with higher frequency. In our 50 kb core 
region, there are ~500 SNPs with MAF < 5%. To generate the chromosomes for an 
individual, we randomly selected two chromosomes {H1, H2} from the remaining 9000 
chromosomes that were not selected as external reference. The disease status of the 
individual was assigned according to 
P(affected | {H1,H2}) = f0 × GRRjI (Hk , j=aj )
j=l
mc
∏
k=1
2
∏ , 
in which f0 is the baseline penetrance and was fixed at 10% in our simulations (1% and 
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5% were also evaluated and resulted in similar patterns but with slight power loss), mc is 
the number of causal SNPs, and aj is the rare allele of SNP j. Sampling was repeated until 
the desired number of cases and controls was reached. In our simulations, d took values 
from 10% to 50% by an increment of 10%. Among the disease risk influencing loci, we 
set the value of r, the percentage of rare alleles increasing disease risk, at 5%, 20%, 50%, 
80%, and 100%, respectively. 
For each of the 100 regions, two independent data sets with 1000 cases and 1000 
controls were simulated with the model described above. In addition, five independent 
null data sets of the same sample size were simulated, assuming no genetic effect by 
randomly sampling 4000 chromosomes (i.e., 2000 individuals) from the pool of 9000 
chromosomes. Average power was estimated based on the 100 regions, which represent a 
wide range of LD patterns. To account for local LD differences, we permuted each of the 
null sets 200 times to obtain region-specific empirical significant threshold. For the 
weighted haplotype analysis, we considered two versions: WHG, which uses haplotypes 
consisting of GWAS SNPs only, and WHS, which uses haplotypes encompassing both 
genotyped and imputed SNPs. For both the weighted haplotype tests and the weighted 
dosage test, untyped SNPs with Rsq (estimated imputation quality) < 0.3 were discarded 
from subsequent analysis (Y. Li et al., 2009). In all analyses, we used haplotypes 
reconstructed from the unphased genotypes and imputed genotypes for markers that are 
not included on the GWAS chip. Our methods (WHG, WHS, and WDS), together with 
WSall, WSrare, HG, and RVC, were applied to the 1000 null data sets within each region to 
determine the region-specific empirical significance threshold, ensuring the correct type I 
error rate of 0.05 for all tests. 
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3.3 Results 
Figure 3.1 shows the empirical power of our methods relative to the other four 
methods proposed in the sequencing context as a function of r, the proportion of rare 
alleles increasing disease risk, which ranges from 5% to 100%. We fixed PAR at 0.5% 
and d (percent of disease-influencing rare variants) at 50%. Although the synergy 
assumption is more reasonable for rarer alleles than for common alleles because rarer 
alleles tend to disrupt gene function, our knowledge regarding the direction of rarer 
alleles is still limited. Therefore, methods robust to such an assumption are desirable. 
Although all methods have decreased power when rare alleles work in different 
directions, our methods performed better by explicitly modeling the direction of 
association. For example, compared with the haplotype grouping (HG) method, the 
advantage of our weighted haplotype method (WHG, on GWAS SNPs only without the 
aid of external sequencing data) manifests more when a larger proportion of the rare 
alleles is protective: power gain is 9.1% when all of the rare alleles at disease- 
contributing loci increase disease risk, and the power gain increases to 20.7% when only 
5% of the rare alleles increase disease risk. 
Our proposed tests increase power through two different mechanisms: by using 
haplotypes to better capture information for rare variants (mostly untyped in GWAS) and 
by using external sequencing data to impute rare variants. Let us consider the first 
mechanism by examining tests on GWAS data alone, namely WHG, HG, WSall, WSrare, 
and RVC. At GWAS level, haplotype-based methods clearly manifest their advantages. 
Among the five methods, the two haplotype-based methods (WHG and HG) rank as the 
best two across the five scenarios presented in Figure 1. Note that WSall and WSrare can be 
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viewed as special cases of WDS, where the dosages only take values 0, 1, or 2 at directly 
genotyped markers. Therefore, at the GWAS level, haplotype-based methods are 
preferred over single-marker dosage-based tests. This is because causal rare variants are 
better captured by haplotypes constructed from GWAS SNPs than by those SNPs 
themselves. Between the two haplotype-based methods, our weighted haplotype method 
(WHG) increases power by an average of 13.2% over HG by weighting individual 
haplotypes (instead of lumping them together into groups) and by explicitly modeling the 
direction of association. 
Next we consider the second mechanism by looking at tests that incorporate 
external sequencing data, namely WHS and WDS. Both are more powerful than WHG, 
the best test based on GWAS data alone. The average power gain of WHS and WDS over 
WHG is 3.8% and 22.0%, respectively. At this pseudo-sequencing level (i.e., study 
subjects imputed with SNPs of sequencing density), a single-marker dosage-based test is 
more powerful than haplotype-based methods. This is not surprising because, at the 
pseudo-sequencing level, causal rare variants are better captured by their imputed 
counterpart than by haplotypes. The same applies to data at the sequencing level (i.e., 
when study subjects are directly sequenced). Of course, if there are genuine haplotype 
effects, we anticipate that WHS will perform better. To quantify the extent of better 
performance, we need more empirical data on the distribution of genuine haplotype 
effects, which is beyond the scope of this paper. Currently, we have little evidence even 
to convincingly conclude the presence of genuine haplotype effects. Therefore, with the 
presence of external sequencing data and under the assumption that single variants,
cumulatively, contribute to disease risk, we recommend WDS over WHS.
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Figure 3.1. Comparison of Power by r: Percent of Rare Alleles in the Causal Region 
that Increase Disease Risk Power of all tests was assessed at the 5% level by using 
empirical significance threshold determined by 1000 null data sets per region. 50% of the 
rare alleles in the causal region were assumed to contribute to disease risk (i.e., d fixed at 
50%), and the PAR of each contributing SNP was fixed at 0.5%. 
 
Figure 3.2 shows the power of different tests under situations with varying PAR 
and varying percentage of disease-contributing rare variants. We fixed the value of d 
(percentage of rare alleles influencing disease risk) at 100%. The value of r (percent of 
causal alleles increasing disease risk) was fixed at 50% for Figure 3.2a, and the per SNP 
PAR was fixed at 0.5% for Figure 3.2b. Although the power decreases with decreasing 
PAR or decreasing percentage of disease-contributing variants for all methods, our WHG 
and WHS are comparable, if not slightly better, than other alternatives, and our WDS is 
more powerful than the other methods by utilizing sequencing information from external 
data and explicitly modeling the SNP-level dosages. 
We note that tests on rare GWAS SNPs only (WSrare and RVC) are less powerful 
in general, because at GWAS marker density, a typical gene region may contain few, if 
any, directly genotyped rare variants. In our simulations, 64 out of the 100 regions have 
no rare variants within the ~50 kb core causal regions. These tests, proposed in the 
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sequencing context, are thus not suitable for analyzing GWAS data. 
Figure 3.2. Comparison of Power by PAR and d: In figure 3.2a, power of all tests was 
assessed at the 5% level by using empirical significance threshold determined by 1000 
null data sets per region. 50% of the rare alleles in the causal region were assumed to 
contribute to disease risk (i.e., d fixed at 50%), and all contributing rare alleles were 
assumed to increase disease risk (i.e., r fixed at 100%). In figure 3.2b, power of all tests 
was assessed at the 5% level by using empirical significance threshold determined by 
1000 null data sets per region. All rare alleles in the causal region were assumed to 
increase disease risk, and the PAR of each contributing SNP was fixed at 0.5%. 
a.      b. 
     
Encouraged by results from simulations, we applied our methods to real data. 
Multiple common and rare variants in IFIH1, a cytoplasmic helicase that mediates 
induction of interferon response to viral RNA, have been established to influence risk of 
T1D. In particular, variants disrupting IFIH1 function have been suggested to confer 
protection from T1D (Nejentsev et al., 2009). We took the WTCCC T1D data to search 
for rare variants associated with T1D susceptibility. In the WTCCC GWAS data set, 10 
SNPs were found in the IFIH1 region, with four being monomorphic in both the T1D set 
and the two control sets (NBS and 58C), leaving six SNPs for analysis. These six SNPs 
and their allele frequencies among cases and controls are tabulated in Table 3.2. We 
applied our methods, along with the others, to this data set. Because the common SNP 
rs1990760 (MAF > 30%) in IFIH1 has been found to influence T1D risk (Barrett et al., 
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2009; Smyth et al., 2006), we restricted our analysis to SNPs or haplotypes with 
frequency < 5% to rule out signals due to LD with rs1990760. Our goal is to assess 
whether there is any residual association with T1D because of rare variants, which have 
been ignored in the previous GWAS analysis. We used the March 2010 release of 60 
CEU individuals from the 1000 Genomes Project as reference for imputation. We used 
SNPs in the ~50 kb IFIH1 gene region plus 2 Mb flanking on each side for phasing and 
imputation. Again, we discarded imputed SNPs with Rsq < 0.3. For the haplotype 
grouping method, the original test failed in this data set because rare alleles in IFIH1 are 
associated with decreased risk of T1D. P-values based on 100,000 permutations are 
shown in Table 3.3. The p values from our methods are in the order of 10-3, whereas the 
most significant p value from existing methods is >0.17. This example clearly 
demonstrates the importance of using appropriate methods when searching for the effect 
of rare variants with GWAS data. 
Table 3.2. Allele frequencies of six polymorphic SNPs in IFIH1 
SNP 58C NBS T1D 
rs3747517 27.66% 26.31% 24.16% 
rs41463049 1.12% 1.06% 1.02% 
rs6432714 1.18% 1.06% 1.02% 
rs13023380 48.88% 47.46% 45.24% 
rs7559193 0.17% 0.10% 0.00% 
rs12479125 1.18% 1.06% 1.02% 
 
Table 3.3. Permutation p-values based on 10,000 permutations, for the association of 
rare variants in IFIH1 with T1D risk in WTCCC data set 
Test p-value 
WDS 0.00431 
WHS 0.00738 
WHG 0.00746 
HG 1.000 
WSrare 0.329 
RVC 0.179 
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3.4 Discussion 
In summary, we have proposed two tests to assess the impact of multiple rare 
variants on disease risk. We show through simulations and a real-data example that by 
maximally extracting information from GWAS data, as well as the incorporation of 
publicly available sequencing data, our methods provide an intermediate solution for the 
analysis of rare variants before study-specific sequencing data become available. Our 
results suggest that at the GWAS level, haplotype-based methods are more powerful, but 
at the pseudo-sequencing level (i.e., GWAS data imputed with publicly available 
sequencing data), a test based on weighted sum of single-marker dosages is more 
powerful. 
By assuming that we know the 50 kb causal region a priori, we may have 
overestimated the power in the simulations. We thus repeated the experiment by 
extending the test region to 100 kb (25 kb flanking region on either side of the core 
region) and to 200 kb (75 kb flanking on either side) to mimic the lack of knowledge on 
the lengths of regulatory regions flanking a gene or an exon. We found that the power 
difference is within 2%. In most situations, power was slightly lower, but in a few 
situations, power was slightly higher, because some variants in the non-causal flanking 
region happen to tag the causal variants better because of LD. These results are not 
surprising, because our methods can eliminate irrelevant SNPs or haplotypes by 
comparing frequency differences between cases and controls in the training data set. 
The analysis of rare variants with GWAS data is challenging because of several reasons. 
First, SNPs picked by the commonly used GWAS genotyping platforms have poor 
coverage for rare variants in general. Second, we have no catalog of rare variants in our 
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genome, and our knowledge regarding their impact on phenotypic variations is still 
limited. Third, traditional association tests are suitable for the analysis of common 
variants but are generally underpowered for the analysis of rare variants. By utilizing LD 
information and incorporating publicly available sequencing data, we show that hunting 
for rare variants with GWAS data is possible. 
Our methods are proposed for GWAS data, which are still the most commonly 
available type of data for gene mapping studies. In both our simulations and the real data 
analysis of T1D with gene IFIH1, we only have GWAS data on the study subjects. We 
compared our methods with alternatives proposed for sequencing data and demonstrated 
that methods that are specifically targeted for the analysis of rare variants in GWAS 
settings such as ours perform much better than methods that are developed for 
sequencing data. We note that our targeted ‘‘rare’’ variants (MAF 0.1%–5%) differ from 
those in methods developed in the sequencing context (including extremely rare variants 
with MAF < 0.5% or 0.1%). For extremely rare variants (MAF < 0.5%), our methods are 
expected to have low power because of low phasing and imputation quality with GWAS 
data. Although our methods are proposed for GWAS data, they can be applied directly to 
sequence data or to partially sequenced data in which selected individuals under study are 
sequenced. Therefore, our methods provide a useful alternative but are not meant to 
replace existing methods, given fundamental differences in their targeted data type 
(GWAS versus sequencing) and targeted MAF range. Because the performance of our 
weighted imputation dosage test depends critically on the imputation quality of rare 
variants (MAF < 5%), we decided to evaluate the quality in real data from the FUSION 
project (Scott et al., 2013) by masking and imputing all rare variants in a subset of 
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individuals with constructed haplotypes encompassing both common and rare variants 
from an independent set of FUSION individuals (of varying sizes) as reference. We 
found that imputation quality for rare variants improves when the sample size in the 
reference panel increases. For example, the accuracy among the heterozygotes (r2) 
increases from 83.4% (74.3%) to 97.0% (92.9%) when the number of reference 
haplotypes increases from 60 to 1000. 
Our methods and others evaluated in this study were developed for the analysis of 
rare variants, but we have found that inclusion of common variants can increase the 
power (data not shown). This is demonstrated by the superior performance of WSall (test 
that includes all variants) over WSrare (test that only includes rare variants), even though 
only rare variants that contribute to disease risk were included in our simulations. This is 
not entirely surprising, because common variants or haplotypes can carry some 
information of untyped rare variants. One major issue of including common variants in 
testing is misclassification, that is, inclusion of variants that do not contribute to disease 
risk. However, by searching for frequency difference in a training set, our methods can 
alleviate this misclassification issue. In general, we recommend testing common variants 
first, for instance, via standard single-marker test. If there is no evidence of association 
with common variants, we then search the entire MAF space for the effect of rare 
variants. When common variants are found to be associated (such as in the IFIH1 
example), we should restrict our attention to rare variants or haplotypes only to alleviate 
the residual effects of common variants. 
Both of our tests assess the effect of multiple variants in aggregate in a predefined 
genomic region, typically a known gene annotated by RefSeq or other gene annotations. 
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For real-life GWAS data, we recommend performing the tests for all known genes if no 
prior knowledge exists or for a list of one or more candidate genes in the presence of such 
knowledge. We note that the weighted dosage-based test is more flexible than the 
haplotype-based test in that it can be used to test for an arbitrary set of SNPs (for 
example, non-synonymous rare SNPs in a pathway), which may involve SNPs on 
different chromosomes. 
One issue with the haplotype-based test is that the haplotypes are not known but 
instead are inferred with uncertainty. Fortunately, most phasing methods, including 
PHASE and MaCH, can estimate the probabilities of possible haplotype configurations 
for each individual in addition to providing the best-guess haplotypes. With these 
estimates, we can easily model the phasing uncertainty into our weighted haplotype test 
by allowing possible haplotype configurations of each individual to contribute to the 
haplotype frequency estimates, as well as to the weighted haplotype score, according to 
their estimated probabilities. An alternative approach is to perform multiple imputation 
on 5–10 imputed data sets (Little & Rubin, 2010). Note that each imputed data set has to 
be drawn from a different posterior distribution to ensure proper multiple imputation. 
This can be achieved either by imputing from different reference sets (for example, from 
bootstrap samples of the HapMap or 1000 Genomes reference set) or by drawing from 
different iteration in a full Bayesian framework in which the model parameters are also 
up- dated in each iteration. Neither approach had noticeable impact on the IFIH1 real 
data set, but further work is warranted. 
Both of our proposed tests can be extended to analyze quantitative traits and to 
accommodate covariates. Both of our tests, in a nutshell, derive one ‘‘genetic score’’ for 
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each individual and assess the association between the genetic score and phenotype of 
interest. The genetic score is a weighted sum of contributing SNP dosages or haplotypes. 
Although the weights are defined for dichotomous trait in this work, we can easily extend 
the work to quantitative traits by first estimating the weights, for the very simple 
example, via regression, then deriving the genetic score accordingly, and finally 
performing the association testing. In the above general setting, covariates can be 
conveniently incorporated. 
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CHAPTER 4: FUNCTIONAL AND STATISTICAL ANNOTATION 
4.1 Introduction 
In this chapter, we present an evaluation of multiple weighting schemes through a 
series of simulations. We evaluate several existing phenotype-independent (Cohen et al., 
2004; Madsen and Browning, 2009; Morgenthaler and Thilly, 2007) and -dependent 
weighting schemes (Wu et al., 2011; Xu et al., 2012), as well as weighting schemes 
determined by linear regression, penalized regression and variable selection methods, 
including Lasso (Tibshirani, 1996), Elastic Net (Zou and Hastie, 2005) and SCAD (Xie 
and Huang, 2009).  We conduct simulations under a variety of scenarios with different 
numbers of true causal variants, mixtures of direction of effect and availability of 
functional information, mimicking sequencing studies of a quantitative trait. We then 
apply each of these methods to a set of high coverage targeted sequencing data (Nelson et 
al., 2012) of 1898 individuals from the CoLaus population-based cohort (Firmann et al., 
2008). 
4.2 Methods 
4.2.1 Statistical Methods 
Over the last few years, numerous sensible weighting schemes have been 
proposed.  In most of these methods a genomic region or variant set is assigned a 
weighted sum over the variants meant to describe the burden of potentially influential 
variants carried by each individual. We call this weighted sum Si. Further, we assume 
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there are N individuals under study, indexed by i, and for each individual we have M 
variants in the region or variant set, indexed by j. 
First, we examine three approaches that are independent of the observed 
phenotype. The first of these is a simple indicator of whether or not rare variants (minor 
allele frequency, MAF < 0.01) are present in the region (Cohen et al., 2004). That is, 
  
where xij is the number of minor alleles observed for individual i at variant j. 
 is the estimated MAF of variant j in the data with pseudo counts and Q is 
the MAF threshold. In this work, we consider Q=0.05. 
Second, we examine a count approach which assigns a higher score to individuals 
carrying a larger number of rare alleles (Morgenthaler and Thilly, 2007); 
Si = I(qˆ j <Q)xij
j=1
M
∑ . 
with xij being the count of rare alleles for individual i at variant j and being the 
estimated MAF, as defined above. 
We also consider the approach proposed by Madsen and Browning (Madsen and 
Browning, 2009) where the weight for variant j is a function of the minor allele frequency 
(MAF): 
, where   
Si = I I(qˆi <Q)xij > 0
j=1
M
∑
"
#
$$
%
&
''
qˆi =
xij +1
i=1
N
∑
2N + 2
qˆ j
1
M
i j ij
j
S xξ
=
=∑ ξ j = 1N × qˆ× (1− qˆ)
 42 
 
with xij and  as above. In the original Madsen and Browning framework for case-
control studies, MAFs are estimated using controls only. However, in this paper, the 
outcome of interest is quantitative and we estimate MAF using the entire sample, which 
makes the method phenotype-independent in this context. 
We also consider phenotype-dependent regression-based methods. First, we 
examine the performance of marginal regression coefficients. That is, we fit the simple 
linear regression model  for each variant j separately and independently and 
then take the fitted values  to be our weights. 
, where , the MLE of  for the model above. 
Though imperfect, this weighting scheme allows investigators to test for associations 
with multiple rare variants in cases where N < M and begin to follow up on individual 
variants that may potentially be of interest. 
Second, we consider weights from ordinary multiple regression, modeling all of 
the M variants simultaneously. That is, we fit the model , where the (i, j)th 
element of the matrix , the minor allele count for individual i at variant j. We then 
take Si to be as above, with the fitted values from this multiple regression,  (Lin 
and Tang, 2011; Xu et al., 2012). 
We also consider weights from several variable selection methods. Such methods 
are appealing since we expect the majority of rare variants not to influence the 
quantitative trait of interest. Use of penalized regression is therefore expected to reduce 
the number of non-zero weights. Similar strategies were recently proposed in the context 
of rare variant association testing (Turkmen & Lin 2012; Zhou, 2010). In penalized 
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regression, we solve for the  which best fit the data, subject to some constraint(s) or 
penalty. That is, instead of minimizing the sum of squared error, , we 
aim to minimize the sum of squared errors and an additional penalty term, 
. In general, the greater the number of parameters included in 
the model, the greater the penalty. A number of penalty functions have been proposed 
and extensively studied in the recent statistical literature (Heckman & Ramsay 2000; 
Hesterberg et al., 2008; Kyung et al., 2010; Wu & Lange 2008). Of these, we chose three: 
the Lasso which imposes a linear penalty (Tibshirani 1996), Elastic Net (EN) which 
imposes a quadratic penalty (Zou and Hastie 2005) and SCAD which is designed to 
penalize smaller coefficients more heavily than larger coefficients (Xie & Huang 2009).  
For Lasso and SCAD, only one tuning parameter, λ, is required. We used the R 
packages lars (Efron, Hastie, Johnstone, & Tibshirani, 2004) and ncvreg (Breheny  
Huang 2011) with default parameter values, which is to choose the optimal λ among a 
grid of 100 possible values equally spaced on the log-scale. For Elastic Net, there are two 
tuning parameters, one for the linear component and one for the quadratic component. 
The linear term, λ1, is chosen in the same way as the λ parameter for the Lasso and 
SCAD methods, discussed above.  The quadratic parameter, λ2, was set to 1 in all 
simulations and for the real data. We used the R package elasticnet to fit the EN models 
(Zou & Hastie, 2005). After model fitting, we then use estimated coefficients from each 
of these variable selection methods as weights. The number of non-zero coefficients 
included is upper-bounded by 100 for each of these schemes throughout this work. 
βˆ 's
(Y −βX)'(Y −βX)
(Y −βX)'(Y −βX)+P(λ,β)
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Under each weighting scheme examined, we determine the significance of a 
genomic region using a score test of the following form:  where 
 in which N is the number of individuals under study, and Yi  is the  
quantitative trait value for the ith individual. Si is the genetic score for the ith individual, a 
weighted sum across multiple variants. Specifically, xij is the number of minor alleles 
observed for individual i at variant j where xij are not normalized. M is the number of 
variants in the region under study (discovered through sequencing in our context) and ξj 
is the weight of variant j under one of the above weighting schemes. The analytical 
distribution for this statistic is not generally known in this context, so significance must 
be assessed empirically by permutation. 
Additionally, we apply the similarity-based method SKAT (Wu et al., 2011) to 
each of our simulated data sets and the real data set for comparison. We use weights 
based on the default Beta distribution implemented in the SKAT package, version 0.79.  
We will comment in the Discussion section on the conceptual differences between the 
weighting schemes we consider in this work and the SKAT methodology. 
4.2.2 Simulation Setup 
We simulate 45,000 chromosomes for a series of 100 50Kb regions with a 
coalescent model [Schaffner et al. 2005] that mimics linkage disequilibrium (LD) in real 
data, accounts for variations in local recombination rates and models population history 
consistent with the CEU samples. We then randomly select 2,000 simulated 
chromosomes (forming 1,000 diploid individuals) to mimic a large sequencing study. For 
each region, we simulate one single pool of 45,000 chromosomes instead of multiple 
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pools of 2,000 chromosomes so that the causal variants in each region can be determined 
by population MAFs (MAFs calculated using the entire population of 45,000 
chromosomes) and thus retained across replicates from the same region.  We assume only 
rare variants (0.001< population MAF <0.05) influence the value of the quantitative trait 
and we randomly select m variants that truly influence the quantitative trait value. For 
each variant, we independently assign the direction of influence according to r, the 
probability that a causal variant will increase the trait value. Following (Wu et al., 2011), 
we then simulate quantitative traits under the null model: 
   (Null model) 
where E1i, E2i and εi  are independent with E1i ~ Bernoulli(0.5) to mimic a binary 
covariate, E2i ~ Normal(0,1) to mimic a continuous covariate, and εi ~ Normal(0,1). We 
also simulate quantitative traits under an alternative model:  
    (Alternative Model)
 
where βj = rj |k × F(MAFj)| and rj = 1 with probability r and rj = –1 with probability (1-
r). E1i, E2i and εi are as before, j indexes the truly causal variants and  is the number of 
minor alleles individual i has at causal variant j. The link function F takes one of the 
following forms: 
, , , 
where N is the number of individuals sequenced. We call the first link function log, the 
second logit, and the third Madsen-Browning (MB). In addition, we also consider 
Frandom(q), a random value chosen from the exponential(1) distribution, independent of q 
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and multiplied by k. The constant k is a scaling factor to control the magnitude of the 
change in quantitative trait due to truly causal genetic variants. In our simulations k is set 
to 0.2, which keeps the heritability h2, between 0.1% and 2.5%. Complex human 
quantitative traits are thought to have heritability estimates in this range (Manolio et al., 
2009). In the Results section, we report the results for the logit link function; results for 
all four link functions are given in the Appendix A. 
To assess significance in each simulated setting, score test statistic from each 
weighting scheme is compared to the empirical distribution of the test statistic obtained 
under the null simulations. We assess the significance of each test at the α=0.01 level 
using the empirical null distribution, which we approximate using 100,000 data sets 
simulated under the null hypothesis of no variant contributing to the quantitative trait. 
For each of the 100 regions we simulate, we randomly select 100 samples of 
2,000 chromosomes (forming 1,000 diploid individuals). We then assign quantitative trait 
values under the null model specified above. Using these 100 × 100=10,000 data sets 
simulated under the null hypothesis, we obtain the empirical null distribution of the test 
statistics for each method. 
We also simulate data under several null hypotheses. For each choice of r, m and 
F(.), we select 2,000 chromosomes from the population of 45,000 chromosomes again via 
simple random sampling. Again, we randomly pair these chromosomes to form diploid 
individuals and replicate 100 times for each region. For each replicate, we randomly 
select m rare variants to be causal. Each causal variant is assigned a direction in which to 
exert its effect (positive with probability r and negative with probability 1 – r).  
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In order to evaluate the effects functional annotation, we must also simulate these 
annotations. In each simulated data set, we annotate variants as “functional” or “non-
functional”. We assume that we have a reasonably good bioinformatics tool such that a 
true causal variant has 90% probability to be annotated as “functional”. Even a perfect 
bioinformatics tool can only predict functionality, not causality or association with a 
particular trait of interest. Because of this, we annotate an additional random number of 
W non-causal variants as “functional”.  Kryukov and colleagues (Kryukov et al., 2009) 
have estimated that approximately one third of de novo missense mutations (that would 
be predicted as functional by a sensible bioinformatics tool) have no effect on phenotypic 
traits. We therefore used 1/3 as the lower bound for the fraction of non-causal variants 
annotated and simulated , rounded to the nearest integer. We evaluate the 
performance of each of these weighting schemes both using all variants without the help 
of the bioinformatics tool, and using only the “functional” variants annotated. Under the 
null distribution, W variants are selected at random. 
In order to simulate GWAS data sets, we use the same choice of causal variants in 
each region as in the simulated sequencing data. Consequently, the direction of 
association and true effect size of each of these are unchanged. In order to simulate 
GWAS SNPs, we select 1000 chromosomes from the total 45,000 to mimic the 1000 
Genomes (Abecasis et al., 2012) sample. The simulated 1000 Genomes sample is used to 
define LD, based on which GWAS SNPs are selected. For each region, we choose 75 
GWAS SNPs consisting of the first 70 tagSNPs (SNPs with the highest number of LD 
buddies where an LD buddy is a SNP with which the r2 >0.8) and 5 SNPs at random from 
W ~ N(25, 5)
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the remaining set of SNPs, mimicking the Illumina Omni5 or Affymetrix Axiom high-
density SNP genotyping platforms. 
4.3 Results 
4.3.1 Results with Simulated Sequencing Data Sets 
First, we compare these methods discussed previously in the absence of a 
bioinformatics tool. Throughout our simulations, we observe several consistent patterns. 
First, when we apply these methods in the absence of a Bioinformatics tool (thus, all 
variants are included in analysis), variable selection schemes (most noticeably Lasso and 
EN) outperform other methods, including SKAT, in nearly all situations (notable 
exceptions are discussed below). For example, under the simulated setting of 10 causal 
variants, among which we expect to five increase quantitative trait value, the power is 
80.0% and 83.7% for Lasso and EN, and is 0.4%, 7.3%, 7.6%, 43.2%, 25.3%, 60.5%, 
41.3%, and 46.6% for Indicator, Count, Madsen-Browning, Marginal Regression, 
Multiple Regression, SCAD, SKAT (all variants), and SKAT (rare variants only) 
respectively (Figure 4.1a). Under the simulated setting of 50 causal variants among which 
40 are expected to increase quantitative trait value, power is 100% for both Lasso and EN, 
and is 0.03%, 0.19%, 0.07%, 99.63%, 100%, 100%, 96.9%, and 98.5% for Indicator, 
Count, Madsen-Browning, Marginal Regression, Multiple Regression, SCAD, SKAT (all 
variants), and SKAT (rare variants only) respectively (Figure 4.1b). 
 
In the presence of a good bioinformatics tool (as introduced in the Methods 
section) the power increases for each of the methods previously discussed. Most notably, 
the phenotype-independent methods show a substantial gain in power once the 
bioinformatics tool is applied. For example, under the simulated setting of 10 causal 
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variants, among which five are expected to increase the quantitative trait value, the power 
is 99.83% and 99.80% for Lasso and EN, and is 23.91%, 17.15%, %, 18.85%, 97.87%, 
99.73%, 99.76%, 98.49%, and 98.34% for Indicator, Count, Madsen-Browning, Marginal 
Regression, Multiple Regression, SCAD, SKAT (all variants), and SKAT (rare variants 
only) respectively (Figure 4.2a). Under the simulated setting of 50 causal variants, among 
which 40 increase quantitative trait value, power is 100% for both Lasso and EN, and is 
99.38%, 98.89%, 96.51%, 100%, 100%, 100%, 100%, and 100% for Indicator, Count, 
Madsen-Browning, Marginal Regression, Multiple Regression, SCAD, SKAT (all 
variants), and SKAT (rare variants only) respectively (Figure 4.2b). Although power 
increases for all methods, the relative performance of the methods changes little from that 
under the absence of a bioinformatics tool.  
Figure 4.1: Power Comparison in the Absence of a Bioinformatics Tool. Figure 4.1 
shows the power (Y-axis) of the different methods across a wide spectrum of m (the 
number of true causal variants) and r (the proportion of variants that contribute to our 
quantitative trait in a positive direction) in the absence of a bioinformatics tool. In Figure 
4.1a, we fix m at 10 and show power comparisons across the entire spectrum of r (X-
axis). Figure 4.1b shows how power changes as a function of m (X-axis) with r fixed at 
0.8. Here we use the logit link function. 
a.              b. 
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Figure 4.2: Power Comparison in the Presence of the Good Bioinformatics Tool. 
Figure 4.2 shows the power (Y-axis) of the different methods across a wide spectrum of 
m (the number of true causal variants) and r (the proportion of variants that contribute to 
our quantitative trait in a positive direction) in the presence of the good bioinformatics 
tool described in the Method section. Like in Figure 4.1a, we fix m at 10 and show power 
comparisons across the entire spectrum of r (X-axis) in Figure 4.2a. Similarly, Figure 
4.2b how power of the methods changes as a function of m (X-axis) with r fixed at 0.8. 
Again the logit link function is used. 
     a.       b. 
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methods. This is to be expected since adding more causal variants increases the signal-to-
noise ratio. When the number of true causal variants is very small, none of the methods 
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SKAT manifests its advantage over other methods examined. As r gets smaller (that is, 
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values gets smaller), the power of the phenotype-independent methods decreases. For 
example, the phenotype-independent methods have close to 0 power when r=0.05; while 
the phenotype-dependent methods are relatively unaffected by changing values of r 
(Figure 4.1a and Figure 4.2a). We also observe a slight dip in power in all of the 
phenotype-dependent schemes when r=0.5 and no bioinformatics information is used 
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canceling one another. Similar trends are seen in all simulations with all four link 
functions (shown supplementary figures 1 and 2). 
4.3.2 Weight Estimation & Identification for Individual Variants 
Table 4.1 shows the correlation between the true and estimated values of the 
weights for each method under the simulation settings in which the number of truly 
causal variants, m, is 10 and the proportion of variants contributing in the positive 
direction, r, is 80%. Of note, the correlation between true and estimated weights increases 
for all methods with the addition of bioinformatics filtering. The Elastic Net and Lasso 
yield the highest correlations between estimated and true weights, both in situations 
where we restrict to variants that are likely to be functional (Pearson correlations of 0.285 
and 0.355), and when we do not (Pearson correlations of 0.744 and 778).  
When using variable selection schemes, we have the opportunity to identify 
individual causal variants within the region or variant set under study. Figure 4.3 
illustrates the accuracy with which the causal variant(s) can be identified by each 
weighting scheme. Note that the causal variant(s) are not always 100% identified, but in 
many cases, the causal variant, or a variant in high LD (r2 > 0.8), have estimated non-zero 
weights. For example, if we fix m=10, r=0.8 and the logit link function, without 
considering LD buddies, we need to consider the top 696 (109 and 12) variants in order 
to detect 90% (60%, 30%) of the causal variants using EN (Figure 4.3a); taking LD 
buddies into consideration, the numbers decrease to 378 (14 and 4) (Figure 4.3b). When 
we also consider functional information we consider fewer variants and narrow the field 
to include a higher proportion of truly causal variants. In this case, we need to consider 
the top 408 (16 and 4) variants in order to detect 90% (60%, 30%) of the causal variants 
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(Figure 4.3c) without considering LD buddies; with LD buddies taken into consideration, 
the numbers decrease to 374 (13 and 3) (Figure 4.3d). 
Figure 4.3: How Far Down the Ranked List are the Truly Causal Variants when All 
Variants are Included? Figure 4.3a shows the number of variants that must be 
considered (Y-axis) in order to catch the top 10%, 20% … 100% of truly causal variants 
(X-axis) in simulation when all variants are considered. We assume that the variants are 
ranked in order of significance. These plots aggregate true and estimated weights from all 
10,000 replicates of the experiment and once again, we fix r at 0.8, m at 10 and use the 
logit link function. Figure 4.3b. takes LD buddies (variants with r2 > 0.8 with causal 
variant) into consideration. Figure 4.3c. restricts the results from 4.3a. to functional 
variants only using a good bioinformatics tool. Figure 4.3d. is restricted to functional 
variants only and takes LD buddies into account. 
a.      b. 
    
c.         d. 
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Table 4.1: Average Pearson Correlation of True and Estimated Weights (m=10 and 
r=0.8) 
Method All markers Limited to functional markers 
Indicator - - 
Count 0.0126 0.2386 
Madsen-Browning 0.0591 0.1225 
Marginal Regression 0.1588 0.6490 
Multiple Regression 0.0883 0.6537 
Lasso 0.2852 0.7436 
EN 0.3555 0.7787 
SCAD 0.2301 0.7344 
SKAT (all) - - 
SKAT (rare only) - - 
 
 
4.3.3 Results with Simulated GWAS Data Sets 
Studies that sequence a portion or the entirety of the genome are becoming increasingly 
common, but still much more GWAS data exist than sequencing data. Imputation has 
been shown to accurately predict genotypes at untyped variants from GWAS data in a 
variety of circumstances [Auer et al., 2012; de Bakker et al., 2008; Li et al., 2010a; Li et 
al., 2009b; Liu et al., 2012; Marchini and Howie, 2010]. Using our simulated GWAS data 
and simulated reference, we observe that variable selection can improve power for 
GWAS data as well. However, the power is consistently lower than that under the 
sequencing setting due to the imperfect rescue of information through imputation 
(comparing Figure 4.1 with Figure 4.4). In our simulations, the imputation accuracy is 
99.66% for all variants and 99.98% for rare variants, but most of the inaccuracies are due 
to missed rare variants. In fact, among variants with MAF < 0.001 nearly all inaccuracies 
are due failure to identify the minor allele. Specifically, the squared Pearson correlation 
between the imputed genotypes (continuous, ranging from 0 to 2) and the true underlying 
genotypes (coded as 0, 1 and 2) is only 0.2397 for variants with MAF < 0.001. 
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Supplementary Figure 3 shows the relative power of these weighting schemes over a 
range of r (Figure 4.4a) and m (Figure 4.4b). 
Figure 4.4: Power Comparison for simulated GWAS data under imputation. Figure 
4.4 shows the power achieved in simulated GWAS data (Y-axis) of the different methods 
across a wide spectrum of m (the number of true causal variants) and r (the proportion of 
variants that contribute to our quantitative trait in a positive direction) in the absence of a 
bioinformatics tool. In Figure 4.4a, we fix m at 10 and show power comparisons across 
the entire spectrum of r (X-axis). Supplementary Figure 4.4b shows how power changes 
as a function of m (X-axis) with r fixed at 0.8. Here we use the logit link function. 
a.          b. 
  
 
4.3.4 Results with Real Data Set 
Of the over 6,000 individuals in the CoLaus cohort [Firmann et al., 2008], 1,898 
had recorded total cholesterol and targeted sequence data in 202 drug target genes 
[Nelson et al., 2012].  Sequencing was done at moderately high coverage (with median 
coverage 27X) and genotype calls were obtained using SOAP-SNP [Li et al., 2009a]. 
Sporadic missing genotypes were imputed with MaCH [Li et al., 2010b]. One gene 
previously known to be associated with total cholesterol in these data is used as a positive 
control. We test each of the 172 autosomal genes with and without removing non-
functional variants using ANNOVAR [Wang et al., 2010]. For each method, we estimate 
weights in association with total cholesterol and, for the methods that accommodate 
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covariates, we adjust for age, age2, sex and the first five principal components. For the 
phenotype-independent methods, no covariate adjustment is performed and significance 
is assessed by permutation of the Yi’s. For methods allowing covariates (marginal and 
multiple regression, Lasso, EN and SCAD), permutation of outcomes alone is not 
appropriate. For these methods, we fit a regression model, Yi ~ Zi, where Z is the matrix 
of covariates and then obtain residuals, . The ’s are then randomly permuted to 
obtain a set of ’s, the permuted residuals. For each permutation, we fit the model 
 in order to re-estimate the weights ξj and scores Si as in [Davidson and Hinkley, 
1997]. We do 10,000 such permutations and, from these, obtain a null distribution of 
statistics with which to assess significance. Since SKAT produces analytical p-values 
shown to preserve type I error [Wu et al., 2011], we use the SKAT analytical p-values 
without permutation. 
When all variants regardless of bioinformatics prediction are included, the 
variable selection methods Lasso and EN yield the smallest p-values compared to other 
methods for the previously implicated gene. However, the previously implicated gene is 
not the most significant among the 172 genes tested. Using ANNOVAR annotations 
[Wang et al., 2010], we restrict to non-synonymous variants in coding regions of the 
genome only. When considering only these functional variants, most weighting schemes 
identify the correct gene with highly significant p-values (Table 4.2 and Figure 4.5). 
 
 
 
 
 
 
 
 
εi εi
ε *i
ε *i ~ Xi
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Table 4.2: Permuted p-values on positive control gene in the real data set 
Method All variants (491) Limited to functional variants (13) 
Indicator 0.208 0.00057 
Count 0.068 0.00017 
Madsen-Browning 0.090 0.00041 
Marginal Regression 0.166 0.00420 
Multiple Regression 0.136 0.00395 
Lasso 0.017 0.00053 
EN 0.008 0.00059 
SCAD 0.111 0.00078 
SKAT (all) 0.329 0.00142 
SKAT (rare only) 0.348 0.00142 
 
 
Figure 4.5: QQ-Plots for p-values in real data. Figure 4.5 shows observed (Y-axis) vs. 
expected (X-axis) –log10(p) values for 172 genes in real data. These p-values are 
computed from the Elastic Net weighting scheme and 10,000 permutations. The gene 
previously implicated in total cholesterol is shown with a green star, all other genes are 
represented by black circles. 
a.           b. 
   
4.4 Discussion 
In summary, through extensive simulation studies with varying number, model, 
and direction of causal variant(s) contributing to a quantitative trait, we find that 
functional annotations derived from good set of bioinformatics tools can substantially 
boost power for rare variant association testing. In the absence of good bioinformatics 
tools, “statistical” annotation based on phenotype-dependent weighting of the variants, 
particularly through variable selection based methods to both select potentially 
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causal/associated variants and estimate their effect sizes, manifests advantages. This 
observation holds for both sequencing-based studies or studies based on a combination of 
genotyping, sequencing, and imputation. We find additional supporting evidence from 
application to a real sequencing-based data set. 
The price one has to pay for adopting phenotype-dependent methods is the 
necessity of permutation, which can be easily performed through permuting of residuals 
for the analysis of quantitative traits (Davidson and Hinkley 1997; Lin 2005) or using the 
BiasedUrn method (Epstein et al., 2012) recently proposed for binary traits. This, in turn, 
increases computational costs. Therefore, we recommend primarily using phenotype-
dependent weighting for refining the level of significance. That is, we recommend 
applying phenotype-dependent weighting only to genomic regions or variant sets that 
have strong evidence of association (but not necessarily reaching genome-wide 
significance) from methods that do not require permutation (for example, SKAT (Wu et 
al., 2011)). 
We note that testing over a region by aggregating information across variants is a 
different task from estimating effect sizes of individual variant (as measured by the 
variant weights in our work). Perfection in the latter (that is, being able to estimate 
weights for each individual variants accurately) leads to perfection in the former (that is, 
maximal testing power over the region harboring those variants), but not vice versa. 
Based on our simulations where we know the true contribution (effect size) of each 
individual variant, we find that individual effect sizes cannot be well estimated (Pearson 
correlation between true and estimated effect sizes < 0.5 even for the best variable 
selection based methods). However, these methods can still increase power of region or 
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variant set association analysis without accurate estimation of individual variant effect 
sizes. In addition, these methods are able to identify the vast majority of the causal 
variants, particularly when LD buddies are considered.  
In this chapter, we mainly consider aggregation of information at the genotype 
level (where we first obtain a regional genotype score via a weighted sum of genotype 
scores for individual variants and then assess the association between the regional 
genotype score and the phenotype of interest), which underlies the largest number of rare 
variant association methods published. In contrast, there are methods that aggregate 
information at the effect size level (for example, SKAT (Wu et al., 2011) where the final 
regional score test statistic is a weighted sum of the test statistics for individual variants) 
or at the p-value level, for example in (Cheung et al., 2012). Our comparisons with 
SKAT suggest that the same conclusions apply to aggregation methods at levels other 
than genotype. 
Lastly, although one could potentially argue that the phenotype-dependent 
methods require an undesirable computing-power trade-off in the presence of good 
bioinformatics tools, in practice, we rarely (if ever) get perfect bioinformatics tools. In 
addition, even perfect bioinformatics tools can only predict functionality but NOT 
causality or association with particular phenotypic trait(s) of interest. Therefore, we view 
that the application of “statistical annotation” through phenotype-dependent weighting, 
particularly using variable selection based methods, to top regions or variant sets 
implicated by computationally efficient phenotype-independent methods, is valuable. 
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CHAPTER 5: SKAT-ADMIX 
5.1 Introduction 
Allele frequencies can differ greatly between populations. This phenomenon is 
called population stratification and, if not properly controlled for, population stratification 
can lead to either false positive or false negative findings. (Choudhry et al., 2006; 
Freedman et al., 2004) A plethora of methods for adjusting for population stratification 
among common variants have been proposed (Epstein, Allen, & Satten, 2007; M. Li, 
Reilly, Rader, & Wang, 2010; Montana & Pritchard, 2004; Price et al., 2006); however, 
(Mathieson & McVean, 2012) show significant evidence that rare variants show stronger 
population stratification than common variants. Further, (Mathieson & McVean, 2012) 
also demonstrate that current methods do not adequately account for population 
stratification among rare variants.  
When dealing with genetic data from an admixed population (that is, a population 
composed of two or more distinct ancestral populations, e.g. African American or 
Hispanic populations), adjusting for population stratification is is especially crucial. In 
admixed populations, information from more than one ancestral population in contained 
within a single individual. Earlier this year, Mao et. al. developed an approach based on 
the WHaIT method discussed in chapter 3 (Y. Li, Byrnes, et al., 2010) to account take 
admixture into account when assessing association between a phenotype and a genomic 
region (Mao, Li, Liu, Lange, & Li, 2013). Mao et. al. combine WHaIT with the Hapmix 
approach for estimating “local ancestry,” that is, the ancestry for each individual at each 
 60 
 
variant locus. This process results in a SKAT statistic and p-value for each ancestral 
population. If desired, the SKAT statistics can be combined using a process similar to 
that used in MetaSKAT (Ionita-Laza, Lee, Makarov, Buxbaum, & Lin, 2013) and SKAT-
O (Lee et al., 2012) 
5.2 Methods 
5.2.1 Splitting SKAT Consider	  a	  genomic	  region	  with	  M	  variants	  typed	  on	  N	  individuals.	  The	  N×M	  genotype	  matrix	  can	  be	  denoted	  X	  with	  (i,j)th	  element	  xij,	  the	  number	  of	  minor	  alleles	  at	  locus	  j	  in	  individual	  i.	  However,	  in	  an	  admixed	  population	  of	  P	  ancestral	  
populations, ,	  where	  Xl	  has	  elements	  xlij,	  the	  number	  of	  minor	  alleles	  from	  
ancestral	  population	  l.	  Throughout	  this	  chapter,	  we	  will	  consider	  only	  two-­‐way	  admixture	  in	  African	  Americans,	  so	  we	  will	  consider	   ,	  where	  XA	  is	  the	  minor	  allele	  count	  matrix	  for	  alleles	  of	  African	  origin	  and	  XE	  for	  the	  alleles	  of	  European	  origin.	  Using	  a	  variety	  of	  previously	  proposed	  ancestry	  estimation	  methods,	  we	  estimate	  the	  minor	  allele	  counts	  from	  each	  parent	  population	  at	  each	  locus	  for	  each	  individual.	  Where,	  in	  truth,	  the	  elements	  of	  XA	  and	  XE	  are	  0,	  1	  or	  2,	  Hapmix	  outputs	  a	  probability	  for	  each	  possible	  combination	  of	  ancestry.	  In	  order	  to	  estimate	  the	  minor	  allele	  counts	  from	  each	  parent	  population	  l,	  we	  consider,	  =	  P[exactly	  one	  minor	  allele	  from	  population	  l]	  +	  2P[two	  minor	  alleles	  from	  population	  l]	  which	  is	  continuous	  in	  [0,2].	  	  Note	  that	  for	  these	  preliminary	  findings,	  no	  threshold	  
X = Xl
l=1
P
∑
X = XA + XE
xˆlij
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on	  the	  probability	  has	  been	  imposed.	  We	  then	  use	  the	  estimated	  matrices	   	  and	  
as	  input	  for	  SKAT	  (Wu	  et	  al.,	  2011),	  rather	  than	  the	  genotype	  matrix.	  
5.2.2 Ancestry Estimation 
The first method examined to estimate local ancestry, “diploid Hapmix,” directly 
estimates the probability of each possible genotype and local ancestry from the genotype 
data using a panel of reference haplotypes from each ancestral population by Hapmix. 
(Price, et. al. 2009) Second, we restrict the diploid Hapmix probabilities to include only 
those that are compatible with the input genotypes. This strategy is motivated by the 
tendency of Hapmix to occasionally miss rare variants because they are indistinguishable 
from sequencing errors. Next, we add a phasing step prior to local ancestry estimation. 
We use MaCH (Y. Li, Willer, et al., 2010) to infer phase information, using an external 
reference haplotype panel. After phasing is complete, we use Hapmix (this time in 
Haploid mode) to estimate the local ancestry of each locus. For comparison, we also use 
MaCH-Admix (Liu et al., 2013) to estimate local ancestry of each locus for the phased 
data only. 
5.2.3 Simulation Setup 
In order to completely evaluate our simulation, we must simulate African 
American chromosomes for which the ancestral population is known for each locus. To 
accomplish this, we first simulate 3000 European and 3000 African chromosomes using 
COSI (Schaffner et al., 2005). Of these, 1000 from each group are set aside to serve as a 
reference panel for the ancestral populations. The remaining chromosomes are used to 
construct simulated 2000 African American chromosomes in concordance with the 
population history of African Americans. First, we construct 425 African American 
XˆAij
XˆEij
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chromosomes containing “switchpoints,” that is cross overs between African and 
European ancestry chromosomes. 425 chromosomes from each ancestry group are 
combined at a randomly determined locus in the region. The crossover map, provided by 
COSI, provides weights for these random assignments and the ancestry of the “first” 
chromosome segment is also determined at random. The remaining 1575 African 
American population chromosomes are pulled from the pool of unused chromosomes so 
far, 1408 African and 167 European. These rates of “switchpoint” occurrence and 
proportion European Ancestry are consistent with the findings presented in (Wegmann et 
al., 2011) and (Parra et al., 1998). These 2000 African American chromosomes are 
randomly paired to form 1000 diploid individuals. 100 replicates of this process were 
preformed. 
Causal variants are chosen from rare variants (MAF<0.05) within one ancestral 
population, either African or European. Though some variants are rare in one ancestral 
population, and not in the other, we consider a variant to be rare, and thus eligible for 
being causal, if it is rare in the population in question. We choose m such variants from 
each ancestral population; values of m considered are 1, 2, 3, 4, 5, 10, 20, 30, 40 and 50. 
Each variant can also contribute to the quantitative trait of interest in the positive or 
negative direction. The probability that a given causal variant contributes in the positive 
direction is denoted by r; values of r considered are 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 
0.9 and 1.0. 
Let the true weight,wj = k × log
qj
1− qj
⎛
⎝⎜
⎞
⎠⎟
 where qj is the MAF of causal marker j. 
Let the set of causal markers be denoted MC and the population from which the causal 
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variants come be denoted k. So, we simulate quantitative trait under the alternative for 
individual i to be, QTi = 0.5E1 + 0.5E2 + wjxlik
j∈MC
∑ , where  E1 ~ Bernoulli(0.5) and  
E2 ~ Normal(0,1). Where E1 and E2 are independent of one another and across 
individuals. Similarly, for the null simulations used to assess type I error, we simulate 
QTi = 0.5E1 + 0.5E2  as in (Wu et al., 2011). 
5.2.4 Real Data 
We also apply these methods, along with the original SKAT, to the African 
American samples from the HeartGO data, part of the Exome Sequencing Project, in the 
APOB gene and 1kb flanking region, which has been previously shown to have a 
population-specific association to LDL cholesterol levels. (Mao et al., 2013) We use 
1000 Genomes reference panels (1000 Genomes Consortium et al., 2010) for European 
(758 samples) and African (492 samples) populations for ancestry estimation. We adjust 
for the covariates, age, sex, BMI, smoking status, and the first 10 principal components. 
There are 7075 samples with valid LDL cholesterol and covariate information and 895 
polymorphic SNPs. 
5.3 Results 
5.3.1 Type I Error 
First, we examine type I error for this method in simulation using the 100 
simulated replicates, with 100 null simulations per replicate, resulting in 10,000 data sets. 
We find that type I error is conserved for both European and African causal alleles as 
illustrated in Table 5.1. 
 
 
 64 
 
 
Table 5.1: Type I Error rates of separate SKAT tests for all methods. 
 
5.3.2 Power 
We compare power of this ancestry-specific analysis compared to the original 
SKAT approach. We find that the power to detect causal alleles of European origin is 
greatly improved compared to the original SKAT method (Figure 5.1), however, when 
the causal alleles are of African origin, the methods are more comparable. It appears that 
the causal African alleles produce signal enough that they can be picked up by the SKAT 
approach without adjusting the data for ancestry (Figure 5.2). The complete results for 
these experiments are shown in Appendix B, figures 1 through 4. 
  
 
 
 
Test For 
SKAT Diploid 
Hapmix + 
SKAT 
Diploid Hapmix + 
Genotype 
Adjustment + 
SKAT 
MaCH 
Phasing + 
Hapmix + 
SKAT 
MaCH 
Phasing + 
MaCH-
Admix + 
SKAT 
European 
Causal 
Alleles 
 
 
0.0491 
 
 
0.0469 
 
0.0384 
 
0.0466 
 
0.0562 
African 
Causal 
Alleles 
 
0.0495 
 
0.0500 
 
0.0447 
 
0.0538 
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Figure 5.1: Power for European causal variants. Figure 5.1a shows power (Y-axis) for 
SKAT Admix and the proposed methods over the number of causal variants m (X-axis) 
when r is fixed at 0.8 and all of the causal variants are of European origin. Figure 5.1b 
similarly shows power (Y-axis) over the proportion of variants contributing in the 
positive direction r (X-axis) for 10 causal variants. For the proposed methods, α=0.025 to 
adjust for multiple comparisons and for SKAT α=0.05. 
a.      b.   
   
 
Figure 5.2: Power for African causal variants. Figure 5.2a shows power (Y-axis) for 
SKAT and the proposed methods over the number of causal variants m (X-axis) when the 
proportion of causal variants that contribute in the positive direction, r, is fixed at 0.8 and 
all of the causal variants are of African origin. Figure 5.2b similarly shows power (Y-
axis) over the proportion of variants contributing in the positive direction r (X-axis) for 
10 causal variants. For the proposed methods, α=0.025 to adjust for multiple comparisons 
and for SKAT α=0.05. 
a.      b.        
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5.3.3 Real Data 
 
 The APOB gene has been previously implicated in LDL-cholesterol levels in 
African Americans (Mao et al., 2013) and the effect is suspected of being European-
specific. (Mao et al., 2013) Here, we implement each of the proposed strategies in the 
APOB gene and 10kb flanking region to 7,075 of the African American samples in the 
HeartGO data for association with LDL cholesterol. The HeartGO data are whole exome 
data with >10x coverage exome-wide. We adjust for sex, age, BMI, smoking status and 
the first 10 principal components. P-values for each of the proposed methods are shown 
in Table 5.2. 
Table 5.2: P-values for individual SKAT tests for APOB in African Americans in 
association with LDL-cholesterol. 
 
5.4 Discussion 
 The results presented above demonstrate that the power of SKAT to detect 
ancestral population-specific associations is greatly improved by first directly estimating 
local ancestry and running SKAT, either separately or in combination. Type I error is 
well preserved in the individual tests and in the proposed combined test. The real data 
example of LDL-cholesterol supports these findings and was able to significantly 
replicate the findings of (Mao et al., 2013) for a European ancestry-specific effect of rare 
 
 
 
 
Test For 
 
 
SKAT 
 
Diploid 
Hapmix + 
SKAT 
Diploid Hapmix 
+ Genotype 
Adjustment + 
SKAT 
MaCH 
Phasing + 
Hapmix + 
SKAT 
MaCH 
Phasing + 
MaCH-
Admix + 
SKAT 
European 
Causal 
Alleles 
 
 
 
0.0818 
 
2.61 x 10-8 
 
1.40 x 10-8 
 
2.31 x 10-8 
 
8.23 x 10-9 
African 
Causal 
Alleles 
 
0.311 
 
0.300 
 
0.327 
 
0.331 
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variants in the gene APOB. As we might expect, association with rare variants from the 
European population is more difficult than association with rare variants from the African 
population since the majority of the samples have primarily African ancestral alleles. 
Further, when the true causal variants are from the European population, haplotyping and 
using MaCH-Admix to estimate ancestry also improves power a great deal by providing 
more accurate ancestry estimation. The observed gain in power comes at a computational 
cost, since we must use MaCH to haplotype the genotype data and then run MaCH-
Admix to estimate ancestry, which takes approximately two times the computational time 
as running Hapmix. Looking forward, combining the processes of phasing and ancestry 
estimation may improve computational time and allow for the implementation of MaCH-
Admix in this context on a larger scale. 
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CHAPTER 6: CONCLUDING REMARKS 
 This document presents several novel methods for aggregation of rare variants 
within a genomic region and makes reference to many more. While each method is 
intended for a specific study design and involves a variety of statistical and 
computational tools, the central goal remains the same: to maximize and aggregate signal 
from truly associated rare variants and to minimize noise from sequence variation that 
does not contribute to the trait of interest. We have demonstrated that various statistical 
methodology can be used to aggregate across rare variants to improve power to detect 
associations while maintaining acceptable type I error rates. In GWAS data, we found 
that adding information from external sequencing data via imputation can improve power 
to detect associations between human traits and rare variants not typed by GWAS, 
particularly when we restrict the variants considered to those which are likely to have an 
effect and when we adjust the sign. In sequence data, we found that directly estimating 
the contribution of each variant greatly improves power over existing methods, however 
the estimation of this contribution is not generally accurate at the marker level and is 
comparatively quite computationally intensive. Similarly, we adapted the SKAT 
approach for admixed populations and found that the most computationally intensive 
methods of estimating ancestry perform best and consequently lead to the highest power, 
however these methods are also the most computationally intensive. 
In general, the proposed methods which control for more confounders and 
estimate genetic effects most directly have the most statistical power to detect 
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associations. However, while more computationally intensive methods tend to perform 
better, they generally come at a computational cost. As molecular technologies become 
more accurate and less cost-prohibitive, many investigators are aiming to run tests like 
these on many regions on the genome. For this reason, the balance between 
computational price and method performance must be considered for these methods in 
order to ensure that they get used and serve their intended purpose.  
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APPENDIX A: SUPPLEMENTARY FIGURES FROM CHAPTER 4 
Figure A.1: Complete power results for all link functions and all values of m 
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Figure A.2: Complete power results for all linking functions and all values of r. 
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APPENDIX B: SUPPLEMENTARY FIGURES FROM CHAPTER 5 
 
Figure B.1: Complete power results for African causal alleles over all values of m. 
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Figure B.2: Complete power results for African causal alleles over all values of r. 
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Figure B.3: Complete power results for European causal alleles over all values of m. 
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Figure B.4: Complete power results for European causal alleles over all values of r. 
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